

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENTDocket No.
2819.001

Under 37 CFR 1.97(b) or 1.97(c)

In Re Application Of: Aharoni et al.

Application No. Filing Date

10/566,321

01/27/06

Examiner

Unknown

Customer No.

23405

Group Art Unit

1653

Confirmation No.

8281

Title: Combined Treatments Comprising Synthetic Peptide Copolymers For Preventing Graft Rejection

Address to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

Docket No.

2819.001

In Re Application of: Aharoni et al.

JUL 24 2006

Application No. Filing Date

10/566,321

01/27/06

Examiner

Unknown

Customer No.

23405

Group Art Unit

1653

Confirmation No.

8281

Title: Combined Treatments Comprising Synthetic Peptide Copolymers For Preventing Graft Rejection

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☐ The Director is hereby authorized to charge and credit Deposit Account No. _____ as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☐ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

July 20, 2006

(Date)

Signature of Person Mailing Correspondence

Jeff Rothenberg

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Dated: July 20, 2006

Signature

Jeff Rothenberg, Reg. No. 26,429
Heslin Rothenberg Farley & Mesiti P.C.
5 Columbia Circle
Albany, NY 12203
Tel: 518-452-5600
Fax: 518-452-5579
E-mail: jr@hrfmlaw.com

CC:

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

JUL 24 2006

Docket Number (Optional)

2819.001

Application Number

10/566,321

Applicant(s)

Aharoni et al.

Filing Date

01/27/2006

Group Art Unit

1653

*EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AA

Aharoni et al. Eur. J. Immunol 1993, 23, 17-25

AB

Aharoni et al. Immunology Letters, 1997, 58(2), 79-87

AC

Aharoni, Teitelbaum et al. Proc. Natl. Acad. Sci. USA, 1997, 94, 10821-10826

AD

Aharoni, Teitelbaum et al. Transplantation, 2001, 72, 598-605

AE

Fridkis-Hareli et al. Proc. Natl. Acad. Sci. USA, 1994, 91, 4872-4876

AF

Schlegel et al. Proc. Natl. Acad. Sci. USA, 1996, 93, 5061-5066

AG

Sela et al. Bull. Inst. Pasteur. 1990, 88, 303-314

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.